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A B S T R A C T
Objective. To assess the prevalence and risk factors of erectile dysfunction (ED) in HIV patients from the HIV clinic
of a tertiary referral center in Mexico City.
Design. Prevalence was obtained from cross-sectional studies, and the International Index of Erectile Function
(IIEF), a standardized method, was used to assess ED.
Methods. A cross-sectional study was performed in the HIV clinic. Participants completed the IIEF to allow ED
assessment. Information on demographics, clinical and HIV-related variables was retrieved from their medical
records.
Results. One hundred and nine patients were included, with a mean age of 39.9 ± 8.8 years. ED was present in 65.1%
of the individuals. Patients had been diagnosed with HIV for a mean of 92.7 ± 70.3 months and had undergone a
mean 56.4 ± 45.5 months of HAART. The only variable associated with ED in the univariate analysis was
dyslipidemia, and this association was also found in the multivariate analysis (P = 0.01).
Conclusions. ED is highly prevalent in HIV patients. Dyslipidemia should be considered as a risk factor for ED in
HIV patients. Romero-Velez G, Lisker-Cervantes A, Villeda-Sandoval CI, Sotomayor de Zavaleta M, Olvera-
Posada D, Sierra-Madero JG, Arreguin-Camacho LO, and Castillejos-Molina RA. Erectile dysfunction
among HIV patients undergoing highly active antiretroviral therapy: Dyslipidemia as a main risk factor. Sex
Med 2014;2:24–30.
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Introduction
Erectile dysfunction (ED) is deﬁned as theinability to achieve or maintain an erection
for sexual intercourse [1]. It affects approximately
10–20 million men in the USA, with a global
prevalence of 16%, which increases with advanc-
ing age [2]. In Mexico, one study reported a 33.7%
prevalence of ED in young men [3]. ED is a
multifactorial disease and is associated with
comorbidities that include vascular, metabolic,
psychogenic, and neurologic diseases.
Human immunodeﬁciency virus (HIV) is an
RNA retrovirus transmitted through sexual inter-
course, through contaminated blood, or vertical
route. It has become a pandemic infection, and it is
estimated that over 34 million people are infected
worldwide [4]. In Mexico, its prevalence has been
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estimated at 0.4% [5]. AIDS-related mortality has
decreased since the introduction of highly active
antiretroviral therapy (HAART). A longer survival
rate has made chronic degenerative diseases more
prevalent in HIV-infected patients.
ED among HIV patients is estimated to have
a prevalence of 46% [6]. Several studies have
investigated this relationship. HAART therapy,
protease inhibitors, hypogonadism, an increase
in life expectancy in HIV patients, type 2 diabetes
(DM2), depression, dyslipidemia, and direct virus
effect are possible explanations. However, there
are contradictions between studies, which may
indicate that the underlying cause of ED in this
population is multifactorial.
Aim
The aim of our study was to assess the prevalence
of ED in patients on HAART from the HIV clinic
at a tertiary care center in Mexico. We also looked
for demographic and clinical variables that could
be related to ED in this population.
We hypothesized that ED would be more
prevalent in men with HIV undergoing HAART.
We expected that medical comorbidities would
be signiﬁcantly associated with the rate of ED in
these men.
Methods
We conducted a cross-sectional study from
January 2008 to December 2008, in which patients
on HAART from the HIV clinic at our institu-
tion were invited to participate. The study was
approved by the local ethics committee. Once
informed consent was provided by participants,
they completed the International Index of Erectile
Function 15 (IIEF-15) questionnaire [7], in the
validated Spanish version [8]. The erectile func-
tion domain was used to evaluate the patients, and
those with a score of >22 were classiﬁed as indi-
viduals without ED. A score of ≤21 was considered
ED, classiﬁed as mild (score of 21–17), moderate
(16–8), or severe (≤7).
Participants’ medical records were reviewed
for demographic and clinical data. Demographic
variables included age, educational level, sexual
preference, tobacco use, and drug and alcohol
consumption. HIV-related variables included
months since HIV diagnosis, CD4 count nadir,
actual CD4 count, months on HAART, history
of protease inhibitor (PI) use, current PI use, and
use of non-nucleoside reverse transcriptase inhibi-
tors (NNRTIs), nucleoside reverse transcriptase
inhibitors (NRTIs), and integrase inhibitors
(IIs). Comorbidities recorded included DM2,
dyslipidemia (triglycerides >200 mg/dL, total cho-
lesterol >240 mg/dL or both), history of myocar-
dial infarction, hypertension, depression, hepatitis
B infection, and obesity. DM2, dyslipidemia, and
hypertension were diagnosed based on the deﬁni-
tions of the American Diabetes Association [9], the
Adult Treatment Panel III [10], and Joint National
Committee 7 [11], respectively.
An independent-samples Student’s t-test was
performed to compare means between the groups;
while nonparametric variables were compared
using Kruskal–Wallis and Mann–Whitney tests.
A multivariate regression analysis was performed
using the most signiﬁcant variables. All analyses
were performed using Statistical Product and
Service Solutions (SPSS) version 17.0 (IBM,
Armonk, NY, USA). Statistical signiﬁcance was
considered to be P < 0.05.
Results
The ﬁnal sample included 109 patients. The
enrollment procedure is depicted in Figure 1. ED
was found in 71 individuals (65.1%). Mild, mode-
rate, and severe ED were found in 48 (67.6%),
9 (12.67%) and 14 (19.71%) patients, respectively.
The mean age was 39.9 ± 8.8 years; 70.6% were
men who have sex with men (MSM). High school
was the minimum educational level in 75.2% of
the individuals. In patients with ED, 60.5% had a
history of alcohol use, and 38.05% had a history of
patients invited
n = 180
rejected invitation
n = 12
patients excluded
n = 59
incomplete record (n = 5)
no sexual partner (n = 41)
PRAI (n = 7)
abstinence (n = 6)
patients included
n = 168
patients analyzed
n = 109
erectile dysfunction
n = 71 (65.1%)
no erectile dysfunction
n = 38 (34.9%)
Figure 1 Enrollment process. PRAI = passive-role anal
intercourse.
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smoking, while in those without ED these rates
were 50% and 31.6%, respectively. Table 1 shows
the prevalence of these variables in patients with
and without ED.
Mean time since HIV diagnosis and initiation of
HAART was 92.7 ± 70.3 and 56.4 ± 45.5 months,
respectively. A history of PI use was found in
41.3%. Rates of current use of PIs, NNRTIs,
NRTIs, and IIs were 51.4%, 64.2%, 67.0%, and
1.8%, respectively. The prevalence for each group
is displayed in Table 2.
The prevalence rates of DM, dyslipidemia,
obesity, and hypertension were 2.8%, 33.0%,
3.7%, and 4.6%, respectively. Depression was
present in 11.9% of the patients. Hyper-
triglyceridemia was present in 15 patients, while
21 suffered hypercholesterolemia. The difference
in dyslipidemia between groups was the only vari-
able with statistical signiﬁcance, with a prevalence
of 40.8% in patients with ED and 18.4% in those
without ED (P = 0.01). The P values between
groups for the rest of the comorbidities are shown
in Table 3.
A multivariate analysis was performed, and
dyslipidemia was again the only variable that
reached statistical signiﬁcance (P = 0.01). The
variables included in this analysis are shown in
Table 4 and were selected based on associations
that have been found in previous studies [6].
Discussion
We found a 64% prevalence of ED among HIV
patients, which is consistent with the results
reported in other studies (21–86%) [12–17].
Stefano Zona et al. compared IIEF scores in
patients with and without HIV and found a higher
prevalence of ED in those infected with HIV
[18]. Even though non-HIV individuals were not
included as control groups, the prevalence of ED
was higher than the 33.7% found in the general
population in Mexico [3].
More recent studies suggest an important asso-
ciation of ED with HAART. However, there are a
few studies reporting a higher prevalence of sexual
dysfunction in patients before the HAART era [6].
Martínez et al. reported for the ﬁrst time in 1999 a
potential role of protease inhibitors in the devel-
opment of ED [19]. Several studies have sought
for this association, and the results have been vari-
able [6]. PIs are the most commonly associated
drugs. In our study, as in other published papers
Table 1 Demographic and clinical characteristics
Erectile
dysfunction
No erectile
dysfunction P
Age, mean (SD) 40.6 (8.6) 38.8 (9.1) 0.31
Educational level, n (%) 0.38
Below high school 15 (21.1) 5 (13.1)
Above high school 53 (74.6) 29 (76.3)
Missing 3 (4.3) 4 (10.6)
MSM, n (%) 0.27
Heterosexual 13 (18.3) 4 (10.6)
MSM 48 (67.60) 29 (76.3)
Missing 10 (14.1) 5 (13.1)
Alcohol consumption, n (%) 0.28
Actual 43 (60.5) 19 (50)
Previous 9 (12.7) 4 (10.6)
No 19 (26.8) 14 (36.8)
Missing 0 (0) 1 (2.6)
Years of alcohol consumption, mean (SD) 18.1 (9.8) 14.6 (8.2) 0.13
Smoking, n (%) 0.36
Current 27 (38.05) 12 (31.6)
Previous 17 (23.9) 7 (18.4)
Never 27 (38.05) 18 (47.4)
Missing 0 (0) 1 (2.6)
Cigarettes/day, mean (SD) 5.8 (8.4) 8.7 (14.6) 0.43
Tobacco years 15.2 (8.7) 16.4 (10.5) 0.69
Drug consumption, n (%) 0.34
Current 5 (7.0) 3 (8.9)
Previous 14 (19.7) 4 (10.5)
Never 52 (73.3) 31 (81.6)
Missing 0 (0) 0 (0)
MSM = men who have sex with men, SD = standard deviation
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[16,18,20], there was no difference in erectile func-
tion between different drug treatment groups.
It has also been suggested that a longer expo-
sure to PI could explain ED [13]. In our study, the
duration of HAART was not different between
participants with ED and those without ED. In the
review by Crum et al., it was found that the time
on HAART was associated with ED in a univariate
analysis, although it did not reach statistical sig-
niﬁcance in the multivariate analysis [12]. This
association was also found in the univariate analy-
sis in a study by Asboe et al. [20]. They reported
in multivariate analysis an association between
older age (greater than 40 years) and ED [20]. This
relationship has been documented in other studies
[13,15,21]. A possible explanation is that survival is
Table 2 HIV-related variables
Erectile
dysfunction
No erectile
dysfunction P
Months since HIV diagnosis, mean (SD) 87.4 (64.1) 102.6 (80.7) 0.32
CD4 nadir, mean (SD) 210.5 (189.9) 190.7 (168.4) 0.58
Actual CD4, mean (SD) 421.2 (240.9) 464.4 (263.7) 0.40
Viral load, mean (SD) 4,964.3 (20,807.4) 225.9 (852.3) 0.18
Months on HAART, mean (SD) 55.9 (44.1) 57.2 (49.8) 0.90
History of protease inhibitor use, n (%)
Yes 28 (39.4) 17 (39.5) 0.59
No 43 (60.6) 23 (60.5)
Current protease inhibitor use, n (%)
Yes 37 (52.1) 19 (50) 0.83
No 34 (47.9) 19 (50)
Current NNRTI use, n (%)
Yes 43 (60.6) 27 (71.1) 0.28
No 28 (39.4) 11 (28.9)
Current NRTI use, n (%)
Yes 46 (64.8) 27 (71.1) 0.51
No 25 (35.2) 11 (28.9)
Current integrase inhibitor use, n (%)
Yes 2 (2.8) 0 (0) 0.30
No 69 (97.2) 38 (100)
HIV = human immunodeficiency virus, SD = standard deviation, HAART = highly active antiretroviral therapy, NNRTI = non-nucleoside reverse transcriptase
inhibitor, NRTI = nucleoside reverse transcriptase inhibitor
Table 3 Comorbidities
Erectile
dysfunction
No erectile
dysfunction P
IIEF score, mean (SD) 17.8 (6.1) 28.3 (1.5) <0.01
Diabetes mellitus, n (%)
Yes 2 (2.8) 1 (2.7) 0.95
No 69 (97.2) 37 (97.3)
Dyslipidemia, n (%)
Yes 29 (40.8) 7 (18.4) 0.018
No 42 (59.2) 31 (81.6)
Myocardial infarction, n (%)
Yes 0 (0) 2 (5.3) 0.05
No 71 (100) 36 (94.7)
Hypertension, n (%)
Yes 4 (5.6) 1 (2.7) 0.48
No 67 (94.4) 37 (97.3)
Depression, n (%)
Yes 11 (15.5) 2 (5.3) 0.12
No 60 (84.50) 36 (94.7)
Hepatitis B infection, n (%)
Yes 2 (2.8) 0 (0) 0.30
No 69 (97.2) 38 (100)
Obesity, n (%)
Yes 3 (4.2) 1 (2.7) 0.67
No 68 (95.8) 37 (97.3)
SD = standard deviation, IIEF = International Index of Erectile Function
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increased with current HIV treatment, so these
patients may now experience age-related diseases
such as ED [12]. We found no differences in age
between groups (P = 0.31); however, differences
were found when patients were divided into those
older than 40 and those younger than 40
(P = 0.038). It is important to highlight that our
study sample was mainly composed of young
adults, with a mean age of 40 (range 24–64).
In our study, no difference according to sexual
preference could be found. This variable was not
associated with a higher prevalence of ED in pre-
vious studies [18,20]. Sollima et al. found MSM
status to be an independent predictive variable of
ED, although they compared it with intravenous
drug use and not with heterosexuality [22]. It has
been suggested by Zona et al. that sexual function
in MSM should be documented with a modiﬁed
IIEF for a more accurate measurement of erectile
function in this population [18].Coyne et al. vali-
dated the IIEF for MSM in 2010. Our study was
performed in 2008; hence, this new index could
not be used [23]. In one study of MSM, only those
with HIV had a higher prevalence of sexual dys-
function [24]. Sexual preference had no inﬂuence
over how the questionnaire was applied to the
patient. We did not speciﬁcally address this issue.
However, when a patient answered the question-
naire, one of the authors was always available
to answer any doubts regarding its content or
meaning.
Depression in HIV-positive patients has been
associated with ED [20]. This association was
also found with antidepressant therapy in the
multivariate analysis of a large study [14]. Moreno-
Pérez et al. conducted a sub-analysis and found
that lower erectile function as assessed by the IIEF
was associated with depression [13].
Dyslipidemia has not been associated with
ED in HIV patients. In the studies by Asboe
et al. and Moreno-Pérez et al., total cholesterol,
triglycerides, and HDL cholesterol were not
signiﬁcantly different between the groups [13,20].
De Rick et al. aimed at ﬁnding this link as a
qualitative variable, yet found no association [15].
Interestingly, dyslipidemia was the only variable
associated with ED in both univariate and multi-
variate analyses in our study.
Dyslipidemia, DM2, hypertension, and obesity
are known risk factors for ED in the non-HIV
population [25,26]. All of them contribute to
endothelial dysfunction, which is manifested as
a reduction in endothelial nitric oxide synthase
levels [3,25]. This process alters vascular relax-
ation, with a subsequent compromise in blood
ﬂow. High triglycerides and low HDL cholesterol
promote a pro-inﬂammatory and pro-thrombotic
state [3]. Free radical formation and athero-
sclerotic changes have also been postulated as
mechanisms [25,27]. For this reason, ED and car-
diovascular disease have been considered as parts
of the same spectrum of illness [25,28].
Dyslipidemia and other metabolic distur-
bances are highly prevalent in HIV patients and
even more so in those receiving HAART [29,30].
Adverse effects of certain drugs used in HIV
treatment favor metabolic disturbances, but HIV
itself is also implicated [31]. There is informa-
tion that supports a genetic predisposition
towards development of dyslipidemia on receiving
HAART [3,29,31]. The higher prevalence of ED
in our HIV patients might be explained by these
factors.
In an observational study performed by Silva
Torres et al. in Brazil, the authors found an asso-
ciation between dyslipidemia and increasing age
in their HIV population [30]. This supports the
fact that, currently, HIV patients are prone to
suffer diseases associated with aging. Silva Torres
et al. found a prevalence of dyslipidemia of
23%, lower than our ﬁnding of 33%. This may
be explained by a genetic predisposition to this
disorder in our Mexican population. We found
dyslipidemia to be signiﬁcantly related to ED
in our population. A possible explanation is that
this independent factor was not previously found
to be signiﬁcant due to the low prevalence
of this comorbidity. However, in a population
where dyslipidemia is prevalent in a third of the
subjects, similar to that in our study, this vari-
able may be more strongly associated with ED
diagnosis.
Guaraldi et al., in a study of 133 HIV-infected
men, were not able to prove an association
between ED and the metabolic syndrome or its
components, which led them to conclude that
another pathogenetic mechanism explains ED in
Table 4 Multivariate analysis
Covariate variable P
Hazard
ratio 95% CI
Age 0.91 1.00 0.95–1.06
Protease inhibitor use 0.46 1.42 0.56–3.60
Depression 0.12 3.75 0.71–19.76
MSM 0.35 1.88 0.50–7.10
Dyslipidemia 0.02 3.75 1.25–11.28
Erectile dysfunction is the dependent variable
MSM = men who have sex with men, CI = confidence interval
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the HIV population [32]. The population assessed
and the methods used could explain these differ-
ences with the information found in the present
study.
One limitation of our study is that hormone
levels were not assessed. The prevalence of hypo-
gonadism in the pre-HAART era ranged from
15% to 50%, but this has now been reduced
[6,12]. Wasting syndrome, opportunistic infec-
tions, drugs, and viral infections have been pro-
posed as the mechanisms underlying low
testosterone levels [12,15]. Many other authors
have found increased estradiol levels [33]; how-
ever, the review by Collazos implies no relation-
ship between high estrogen levels and ED [6].
Amini et al. found statistically signiﬁcant differ-
ences in the erectile function domain between
eugonadal and hypogonadal patients [34]; while
other studies failed to demonstrate this association
[13,20]. Another limitation of the present study is
that the use of phosphodiesterase 5 inhibitors and
that of statins were not evaluated.
Although anxiety and guilt were not included in
our evaluation, they have been previously assessed
[35]. We also acknowledge that as the aim of this
study was to relate metabolic and clinical variables
with ED in patients with HIV, some other con-
founding variables were not included in our evalu-
ation. In addition, dyslipidemia is unlikely to be
modiﬁed by psychological factors such as anxiety,
depression, or guilt.
Even though our study has the limitations
inherent to any cross-sectional study, dyslipi-
demia could, to some extent, explain ED in
this population. Selection bias is acknowledged
as well; our sample is taken from an HIV clinic,
and the results may be different if compared with
an open population sample. Our ﬁndings are sup-
ported by the fact that dyslipidemia is a common
risk factor for ED in the general population,
the increasing age and age-associated comorbi-
dities in HIV individuals, and the occurrence
of dyslipidemia as an adverse effect of HAART
and HIV itself. According to different studies, it
seems that multifactorial components could be
present. As a precise link between ED and HIV
has not been found, all factors should be studied
individually.
Conclusions
Erectile dysfunction was highly prevalent (65.1%)
in HIV patients undergoing HAART. None of the
variables that have been previously associated with
ED in HIV patients were found to be relevant in
our study. However, we found an association with
dyslipidemia that should be further investigated.
As dyslipidemia was the only variable associated
with ED in our study, it ought to be considered as
a risk factor for ED in HIV patients.
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